DNA testing guides drug selection, cutting trial-and-error treatments

Pharmacogenomics—the intersection of genetics and drug therapy—is reshaping how physicians prescribe medications in clinical practice. By analysing a patient's genetic makeup, doctors can now predict how individuals will metabolise specific drugs, enabling more precise treatment selection rather than relying on conventional trial-and-error approaches.

This advancement holds particular significance for Southeast Asian populations, where genetic diversity often means standardised dosing regimens may be less effective or carry heightened risks for adverse reactions. Genetic variations affect how patients process medications, influencing both efficacy and safety profiles across therapeutic classes ranging from cardiovascular drugs to oncology treatments.

Healthcare systems in the region are gradually integrating DNA testing into clinical workflows, though adoption rates vary. The technology reduces the time patients spend on ineffective medications, decreases hospitalisation from drug-related complications, and potentially lowers overall healthcare costs through more efficient treatment pathways.

As personalised medicine gains momentum across South and Southeast Asia, experts anticipate that genetic screening will become standard practice for managing chronic conditions and complex disease states. Regulatory frameworks and healthcare funding models will play crucial roles in determining how quickly this shift accelerates across the region's diverse healthcare landscapes.